TSE:TH

Theratechnologies (TH) Stock Price, News & Analysis

C$1.80
-0.05 (-2.70%)
(As of 10:02 AM ET)
Today's Range
C$1.79
C$1.81
50-Day Range
C$1.64
C$2.29
52-Week Range
C$1.22
C$5.84
Volume
1,208 shs
Average Volume
37,180 shs
Market Capitalization
C$82.76 million
P/E Ratio
N/A
Dividend Yield
3.76%
Price Target
C$5.50

Theratechnologies MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
205.6% Upside
C$5.50 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.09 out of 5 stars

TH stock logo

About Theratechnologies Stock (TSE:TH)

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

TH Stock Price History

TH Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Here's what Wall Street expects from Theratechnologies's earnings report
7THTX : Theratechnologies Earnings Preview
See More Headlines
Receive TH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
4/24/2024
Next Earnings (Estimated)
7/10/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
103
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$5.50
High Stock Price Target
C$5.50
Low Stock Price Target
C$5.50
Potential Upside/Downside
+197.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
C$-23,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$81.76 million
Cash Flow
C$0.49 per share
Book Value
C($0.45) per share

Miscellaneous

Free Float
N/A
Market Cap
C$85.06 million
Optionable
Not Optionable
Beta
1.73
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Paul Lévesque (Age 59)
    President, CEO & Director
    Comp: $1.6M
  • Mr. Philippe Dubuc M.B.A. (Age 57)
    MBA, Senior VP & CFO
    Comp: $587.17k
  • Mr. Jocelyn Lafond L.L.M. (Age 56)
    LL.B., General Counsel & Corporate Secretary
    Comp: $429.6k
  • Dr. Christian Marsolais Ph.D. (Age 61)
    Senior VP & Chief Medical Officer
    Comp: $590.29k
  • Mr. John Leasure (Age 59)
    Global Commercial Officer
    Comp: $571.68k
  • Hon. Andre Dupras M.Sc. (Age 60)
    Vice President of Human Resources

TH Stock Analysis - Frequently Asked Questions

Should I buy or sell Theratechnologies stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TH shares.
View TH analyst ratings
or view top-rated stocks.

What is Theratechnologies' stock price target for 2024?

2 brokerages have issued 12 month price targets for Theratechnologies' stock. Their TH share price targets range from C$5.50 to C$5.50. On average, they predict the company's stock price to reach C$5.50 in the next year. This suggests a possible upside of 205.6% from the stock's current price.
View analysts price targets for TH
or view top-rated stocks among Wall Street analysts.

How have TH shares performed in 2024?

Theratechnologies' stock was trading at C$2.14 at the start of the year. Since then, TH shares have decreased by 15.9% and is now trading at C$1.80.
View the best growth stocks for 2024 here
.

When is Theratechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024.
View our TH earnings forecast
.

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc. (TSE:TH) issued its earnings results on Wednesday, February, 21st. The company reported ($0.11) earnings per share (EPS) for the quarter. The firm had revenue of $31.93 million for the quarter. Theratechnologies had a negative trailing twelve-month return on equity of 1,116.86% and a negative net margin of 29.30%.

What other stocks do shareholders of Theratechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Stars Group (TSGI), BCE (BCE), ProMetic Life Sciences (PLI), Teranga Gold (TGZ), Nemaska Lithium (NMX), Shopify (SHOP), United Therapeutics (UTHR) and Avigilon (AVO).

How do I buy shares of Theratechnologies?

Shares of TH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:TH) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners